top of page
CoRegen Final Logo-03.png

Our Newsroom

Explore our latest announcements, media coverage, and press releases as we share milestones, breakthroughs, and the momentum behind our mission.

iStock-2164745575_edited.jpg
Chemical works

CoRegen, Inc. Closes More Than $93 Million Financing.

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

iStock-1474770647-modified-6053a6dc-3f10-4ec9-bfb7-8eceade8686a.jpg

CoRegen, Inc. Appoints Biotech Veteran Sonal Gupta, M.D., Ph.D., as Chief Medical Officer
 

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

iStock-2164745575.jpg

CoRegen, Inc. Strengthens Leadership Team with the Appointments of Sonja Nelson as Chief Financial Officer and Peter Gelinas as Chief Technical Officer

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

iStock-1165058710-ai-modified-b505c1bc-c516-4636-828f-bccd336252d6.jpg

CoRegen, Inc. Appoints Globally Recognized Surgeon-Scientist Bert O’Malley Jr. to its Board of Directors

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

iStock-1414624179 (1).jpg

CoRegen, Inc. Publishes Promising New Data Highlighting SRC-3 Engineered Regulatory T Cells as New Immunotherapy Platform

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

CoRegen, Inc. Receives FDA Clearance to Advance CRG-150 into Phase 1/2a Clinical Trials, Pioneering a New Frontier in Cell Therapy for Multiple Solid Tumor Types

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

July 7, 2026

CoRegen, Inc. Publishes Promising New Data Highlighting SRC-3 Engineered Regulatory T Cells as New Immunotherapy Platform

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

March 17, 2026

Bert W. O’Malley (1936–2025): A great scientist, mentor, and proud Irishman

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

March 11, 2026

Cancer-fighting startup CoRegen lands $13.5M, adapts following death of Dr. Bert O'Malley

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

March 10, 2026

CoRegen Appoints Globally Recognized Surgeon-Scientist Bert O’Malley Jr. to its Board of Directors

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

December 22, 2025

CoRegen, Inc. Strengthens Leadership Team with the Appointments of Sonja Nelson as Chief Financial Officer and Peter Gelinas as Chief Technical Officer

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

September 10, 2025

CoRegen, Inc. Appoints Biotech Veteran Sonal Gupta, M.D., Ph.D., as Chief Medical Officer

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

July 31, 2025

CoRegen, Inc. Closes More Than $93 Million Financing

  • 40+ years of pharma and biotech leadership

  • Six companies reached values or sold for $1B+

  • Notably, Medivation was acquired by Pfizer for $14.2B

July 09, 2025

bottom of page